Quisinostat - Janssen Pharmaceutica/NewVac

Drug Profile

Quisinostat - Janssen Pharmaceutica/NewVac

Alternative Names: JNJ-26481585

Latest Information Update: 12 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Pharmaceutica; Janssen Research & Development; NewVac
  • Class Antineoplastics; Hydroxy acids; Hydroxylamines; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lung cancer; Ovarian cancer
  • Phase I Breast cancer; Sarcoma
  • Discontinued Cutaneous T cell lymphoma; Leukaemia; Multiple myeloma; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 05 Jul 2017 Discontinued - Phase-I for Multiple myeloma (Combination therapy) in France (PO) (NewVac and Janssen pipelines, July 2017)
  • 05 Jul 2017 Quisinostat is still in phase II development for Ovarian cancer (NewVac and Janssen pipelines, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top